An observational study in HIV, sponsored by Desmond Tutu HIV Foundation. Not yet recruiting at 1 site in South Africa. Open to participants aged 15 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Desmond Tutu HIV Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The ALIGN study will evaluate the delivery of injectable Lenacapavir (LEN), a long-acting injectable formulation for HIV pre-exposure prophylaxis (PrEP), amongst adolescents and young people (aged 15-35 years) living within the Klipfontein-Mitchell's health sub-district of Cape Town, South Africa. LEN will be offered alongside injectable Cabotegravir long-acting (CAB LA), an injectable PrEP product already approved for use in South Africa, and oral PrEP (F/TDF) modalities (including intermittent dosing where appropriate), the current standard of care (SOC) biomedical HIV prevention in South Africa. Following counselling, participants will be able to choose which PrEP product (LEN, CAB LA, or oral PrEP) to initiate, with the option to switch at any future clinical visit, and followed for 18 months. These options will be offered from two types of delivery sites, namely public health facilities and established mobile service delivery trucks, where various forms of PrEP are currently delivered as part of outreach services and ongoing research studies (FastPrEP UCT HREC nr. 713/2021 and PrEPared to Choose 567/2023).
Lenacapavir (LEN) is a novel, first-in-class, multi-stage HIV-1 capsid inhibitor with high potency and a long half-life, allowing administration by subcutaneous injection twice yearly (1). The PURPOSE 1 study, a phase 3, double-blind, randomized, controlled trial involved adolescent girls and young women in South Africa and Uganda. Purpose 1 study found that none of the participants receiving twice-yearly LEN injection acquired HIV infection (1). Purpose 2, which was conducted amongst cisgender men who have sex with men, transgender, and non-binary populations, reported two incident infections amongst 2179 LEN users. CAB LA is an alternative long-acting injectable formulation administered by intra-muscular injection every two months. CAB LA efficacy and safety was established in the HPTN 083 and HPTN 084 studies, which indicated a 66% and 88% reduction in HIV risk compared to oral PrEP users respectively. The ongoing PrEPared to Choose study, conducted by this study team, (UCT HREC 567/2023) offers CAB LA and oral PrEP products and has demonstrated the feasibility and impact of many of the PrEP choice and delivery processes put forward in this protocol. As such, this study team has extensive experience in CAB LA and oral PrEP real-world delivery.
The ALIGN study will provide one of the first real-world (outside of the clinical trial research site) evaluations of LEN delivery with the view to evaluate firstly, what implementation strategies best support LEN initiation and persistence at the level of the PrEP provider and the PrEP user, and secondly, persistence (defined as consistent, uninterrupted use as prescribed) on LEN compared to alternative injectable products and SOC oral PrEP. The proposed study will utilise a hybrid implementation study design, with co-primary implementation and clinical aims, in the form of a non-randomised, quasi-experimental trial design. Findings from this study will be used to inform the anticipated LEN rollout into public health facilities (including ANC clinics) as well as the implementation of PrEP choice service delivery in a new era of expanded biomedical HIV prevention products. The addition of LEN will build on the experiences of implementing previous long-acting PrEP products (such as injectable long-acting Cabotegravir) and will generate practical insights to inform the scale of this innovative tool while national regulatory approvals are being sought. This will include working with communities to harness their insights and answering specific questions to support effective delivery and drive uptake and effective use of injectable PrEP (LEN and CAB LA).
Study purpose:
To evaluate the delivery strategies (public health facility and community-based) and potential impact of Lenacapavir (LEN) as PrEP, on the relative persistence of up to 3700 young people (aged 15-35 years) initiating on LEN compared to an alternative injectable product (CAB LA) and oral PrEP products (standard of care).
We hypothesize that people who select injectable PrEP will be more likely to persist on PrEP when compared with people who select oral PrEP, and further that injectable LEN will show enhanced persistence compared to injectable CAB LA.
Primary study objectives:
The primary objectives of this study are to distinguish PrEP persistence patterns across different PrEP modalities (oral PrEP vs injectable CAB vs injectable LEN as PrEP) and identify successful implementation strategies that will aid the provision of PrEP choice to adolescents and young people in South Africa from two distinct delivery platforms (public health facilities and mobile services).
This proposed study will utilise a hybrid implementation design (type 2, co-primary implementation and clinical aims), in the form of a non-randomised, quasi-experimental trial design. Clinically, it aims to compare persistence among participants who self-select to use an injectable (LEN vs CAB LA) or oral PrEP modality over an 18-month period. The study will also evaluate potential implementation strategies that could be used to support PrEP adoption, initiation, and persistence at the level of the PrEP provider and PrEP user.
This research study falls within the initial implementation stage, as this will be the first post-efficacy study use of LEN amongst young people in the South African setting. This study will evaluate the delivery of LEN from both public facilities (including antenatal care services) and community settings (including mobile clinics) as well as explore methods of demand creation and choice promotion counselling within the broader PrEP offerings. Sites must be willing to administer LEN and have appropriate equipment to support administration.
This research study falls within the initial implementation stage, as this will be the first post-efficacy study use of LEN amongst young people in the South African setting. This study will evaluate the delivery of LEN from both public facilities (including antenatal care services; ANC) and community settings (including mobile clinics based in the community), as well as explore methods of demand creation and choice promotion counselling within the broader PrEP offerings.
Participants will be enrolled from a general population aged 15-35 years and will aim to include people from these groups: adolescent girls and young women (AGYW, including women who trade sex); young cis-gender men including men who have sex with men, MSM); and pregnant and lactating people.
Two mobile clinics and one public health facility will be pre-selected to host the ALIGN Project . Participants accessing sexual and reproductive health services and/or ANC services at the pre-selected public health facility, including existing PrEP users coming for product refills, will be invited to enrol on the ALIGN project. If enrolled on ALIGN, they will be able to select their preferred PrEP modalities (oral or injectable) to use for the duration of the study (18 months), with product switching allowed at any subsequent visit.
The aims of the ALIGN study are as follows:
Primary aim:
Secondary aims:
Exploratory aims:
This study will offer PrEP choice amongst oral PREP (up to n=700), injectable CAB (up to n=1500), or injectable LEN as PrEP (up to n=1500). Individuals in this study will be followed for 18 months, with clinical visits timed according to product refills (oral PrEP) or administration (injectable PrEP). Missed visits will be monitored and individuals will be able to "cycle back" (i.e. return following a missed visit) at any time within the duration of the project. Participants will be allowed to switch between PrEP products according to their preference throughout the study.
Adherence is defined as on-time receipt of injections within the specific study product window (within 28 days for oral PrEP, 7 days for CAB LA, within 14 days for LEN).
Persistence is defined as continuous use of product as intended. This will be measured in two ways:
Longitudinal view of persistence: time to meet criteria for non-persistence from baseline.
Both views are necessary to assess the efficacy of real-world products in real-world settings where longitudinal persistence (time to persistence) alone fails to capture dynamic PrEP use behaviour.
Various implementation strategies to support PrEP adoption, initiation, and persistence will be implemented, monitored and reported on using a RE-AIM implementation science framework.
Primary endpoints are:
(i) Time to reach any participant sample size first (either LEN arm (n=1500), oral PrEP modalities (n=700), or CAB arm (n=1500). I.e. this endpoint will be reached once any one of the arms is fully recruited, however enrolment will continue until both the CAB LA and LEN arms have reached sample size (n=1500 respectively) (ii) Proportion of participants reached within community vs facility-based settings (iii) 12 month persistence for injectable LEN vs CAB LA vs oral PrEP. (iv) Time to missed oral or injectable PrEP pick up/visit
Secondary endpoints are:
(i) 18-month durable persistence for injectable LEN vs CAB LA vs oral PrEP (ii) Time on PrEP based on any PrEP product
Desmond Tutu HIV Foundation is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
People accessing the sites (mobile clinics in Cape Town, South Africa) for general sexual and reproductive health services including PrEP will be invited to consecutively enrol on the ALIGN project. If enrolled on ALIGN, they will be able to select their preferred PrEP modalities (oral PrEP, LEN or CAB LA) to use for the duration of the study (18 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must be negative at baseline
- 15-35 years
Exclusion Criteria:
Confirmed -positive test result and/or signs and symptoms of an acute HIV infection
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenacapavir given every 6 months for HIV prevention.
CABLA given every 2 months as HIV prevention
Oral PrEP (TDF/FTC) taken daily for HIV prevention
To compare persistence between PrEP modalities (injectable LEN vs injectable CAB LA vs oral PrEP) longitudinally (time to non-persistence) and segmentally (total time over which biomedical coverage of HIV exposure is achieved.
Persistence is defined as continuous use of product as intended. This will be measured in two ways: 1\. Longitudinal view of persistence: time to meet criteria for non-persistence from baseline. This view will be presented through a Kaplan-Meier analysis. • Non-persistence: Defined as \>28 days gap in PrEP availability for daily dosing (oral PrEP); \>28 days gap in scheduled CAB LA injections as per pharmacy records; and as a ≥14 days gap following a scheduled LEN injection * Non-persistence may also arise if a participant discontinues PrEP but then recommences PrEP within the study timeline. * If a participant switches to using another PrEP product (with less than 14 day gap between products), they will be considered non-persistent on that individual PrEP product but persistent on PrEP overall. * If a participant defers a LEN or CAB LA injection for scheduling reasons, oral may be used as a "bridge" between injections. Participants that bridge will be defined as persistent.
Time frame: Measured at 6, 12 months and 18 months
Plan to share: Yes — All IPD collected through the trial.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Protocol will be made available in the form of a published protocol paper. High-level, de-identified operational data on PrEP use patterns will be shared with the National Department of Health on monthly basis from first enrollment to end of study in March 2028.
Access criteria: PI and co-Is at each site will control all rights to the data and intellectual property obtained from this project. To ensure confidentiality, data shared with project team members will be blinded (i.e. delinked from identifying participant information). All data transferred between investigators will be done securely through password-protected files. High-level, de-identified operational data on PrEP use patterns will be shared with the National Department of Health as per the national reporting stationary. All pregnancies amongst participants using LEN, CAB LA or TDF/FTC and occurring during the study, along with their outcome, will be recorded and reported to SAHPRA, UCT HREC as well as the study's collaborating partners (Gilead Sciences in the case of pregnancy while using LEN) irrespective of their association with an AE or SAE. The pregnancies will be registered on the Gilead Sciences Patient Safety Database and Viiv Healthcare/ GSK.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Mar 2028, 26 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Desmond Tutu HIV Foundation